Summary

The global interventional cardiology devices market is projected to reach USD 27.80 billion in 2024 and is projected to reach USD 37.27 billion by 2029, at a CAGR of 6.0% during the forecast period.

The growth of the interventional cardiology devices market is driven by several key factors, most notably the increasing prevalence of cardiovascular diseases (CVD) worldwide, advancements in minimally invasive procedures, and growing demand for improved patient outcomes. As rates of heart disease, hypertension, and diabetes rise, the need for effective treatments such as angioplasty, stenting, and valve replacements also increases. Technological innovations, including the development of drug-eluting stents, bioresorbable scaffolds, and advanced imaging technologies, have enabled safer and more precise procedures, which contribute to the market’s growth.

“Based on the angioplasty balloons type, the old/normal balloons segment is expected to grow by the highest CAGR in the interventional cardiology devices market.”
Traditional angioplasty balloons, also known as plain old balloon angioplasty (POBA), offer several advantages over drug-eluting balloons (DEBs) in certain clinical scenarios. First, traditional balloons tend to be less costly than DEBs, making them a more accessible option for healthcare systems and patients, especially in regions with limited healthcare budgets or where reimbursement policies may not fully cover DEB, also POBA also has a simpler mechanism—it dilates narrowed blood vessels by compressing plaque against the vessel walls without releasing drugs, which can be beneficial in cases where the risks associated with drug delivery aren’t justified. For example, in acute settings like treating certain types of arterial blockages where drug-delivery isn’t critical to outcomes, POBA may provide sufficient clinical results without the added complexity or cost of drug elution.

“The embolic protection devices segment in hemodynamic flow alteration devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market.”
Embolic protection devices (EPDs) are a vital advancement in interventional cardiology, designed to capture and remove debris that may dislodge during vascular procedures, thereby minimizing the risk of embolization. These devices are particularly beneficial during interventions like carotid artery stenting, where dislodged particles could travel to the brain and cause strokes. By capturing such debris, EPDs significantly reduce periprocedural stroke risks and improve the safety profile of these interventions.

“The guidewires segment in other devices segment is expected to grow with the highest CAGR in the interventional cardiology devices market.”
Guidewires are essential in interventional cardiology, offering precision, flexibility, and control that enhance the safety and effectiveness of procedures like angioplasty and stent placement. These thin, flexible wires guide catheters through blood vessels, allowing clinicians to navigate complex vascular structures and reach targeted areas with minimal trauma to surrounding tissues. Their superior torque response and maneuverability help cardiologists access difficult-to-reach lesions, improving procedural success rates and reducing the need for open surgery.


“Based on the end user, hospitals segment is expected to grow by the highest CAGR in the interventional cardiology devices market.
Most interventional cardiology procedures, such as angioplasties, stent placements, and structural heart interventions, are carried out in hospitals because they boast special facilities and the sophisticated imaging technologies that would treat a patient with maximum quality. They are well equipped both for simple and complicated processes with a good staff; besides, they are where they can be managed whenever a complication arises. These settings enable cardiologists to take the latest tool systems into practice, including drug-eluting stents, rotational atherectomy and intravascular ultrasound, to ensure utmost precision and safety for patients.


“Asia Pacific to grow with the highest CAGR in the interventional cardiology devices market during the forecast period.”
The Asia-Pacific region is also expected to experience maximum growth in the interventional cardiology devices market in the next few years due to several key factors. Growth is driven by an increasingly aging population, the growing prevalence of cardiovascular diseases, and increased adoption of minimally invasive procedures, especially in countries such as China, Japan, and India. Increased healthcare expenses and development of health infrastructure promote the availability of high-end interventional cardiology services throughout the region.

The break up of the profile of primary participants in the interventional cardiology devices market:
• By Company Type: Tier 1- 35%, Tier 2- 45%, and Tier 3-20%
• By Designation: C-level Executives- 35%, Directors- 25% , and Others- 40%.
• By Region: North America - 40%, Europe – 30%, APAC –20%, Latin America – 5%,Middle East & Africa–5%

Key players in the interventional cardiology devices market
Some of the prominent players operating in the interventional cardiology devices market include Boston Scientific Corporation (US), Medtronic (US), Abbott (US), B. Braun SE (Germany), Terumo Corporation (Japan), Edwards Lifesciences Corporation (US), Koninklijke Philips N.V. (Netherlands), Integer Holdings Corporation (US), Teleflex Incorporated (US), Penumbra, Inc. (US), Cook (US), Cordis (US), iVascular S.L.U (Spain), Biosensors International Group, Ltd (Singapore), BIOTRONIK SE & Co. KG (Germany), AMG International (Germany), ENDOCOR GmbH (Germany), InSitu Technologies, Inc. (US), Meril Life Sciences (India), Alvimedica (Istanbul), Cardionovum GmBH (Germany), Medinol Ltd (Turkey), Wellinq (Netherlands), Balton SP (Poland), Translumina (India).

Research Coverage:
The report analyzes the interventional cardiology devices market and aims at estimating the market size and future growth potential of this market based on various segments such as angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices and end user. The report also includes a product portfolio matrix of various interventional cardiology technologies available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report
The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall interventional cardiology devices market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, challenges, and opportunities.
This report provides insights into the following pointers:
• Of Analysis of key drivers (growing prevalence of cardiovascular diseases, technological advancements in interventional cardiology procedures, increased prevalence of diabetes & growing product launches by leading players in developing countries), restraints (availability of alternative treatments & recall of products by industry participants to limit the uptake of interventional cardiology equipment), opportunities (high growth potential in emerging markets & growing coronary stent demand in developing countries) and challenges (stringent regulatory requirements delaying the approval of cardiac devices).
• Product Enhancement/Innovation: Comprehensive details about new product launches and anticipated trends in the global interventional cardiology devices market.
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the global interventional cardiology devices market
• Market Development: Comprehensive information on the lucrative emerging markets by angioplasty stents, structural heart devices, catheters, angioplasty balloons, plaque modification devices, hemodynamic flow alteration devices, other devices and end user.
• Market Diversification: Exhaustive information about new product and services or product and service enhancements, growing geographies, recent developments, and investments in the global interventional cardiology devices market.
• Competitive Assessment: Thorough evaluation of the market shares, growth plans, offerings of product and services, and capacities of the major competitors in the global interventional cardiology devices market.

ページTOPに戻る

Table of Contents

1 INTRODUCTION 29
1.1 STUDY OBJECTIVES 29
1.2 MARKET DEFINITION 29
1.3 MARKET SCOPE 29
1.3.1 MARKET SEGMENTATION 30
1.3.2 INCLUSIONS & EXCLUSIONS 31
1.3.3 YEARS CONSIDERED 31
1.3.4 CURRENCY CONSIDERED 31
1.4 MARKET STAKEHOLDERS 32
1.5 LIMITATIONS 32
1.6 SUMMARY OF CHANGES 32
2 RESEARCH METHODOLOGY 34
2.1 INTRODUCTION 34
2.1.1 SECONDARY RESEARCH 35
2.1.2 KEY DATA FROM SECONDARY SOURCES 36
2.1.2.1 Primary data 36
2.1.3 KEY DATA FROM PRIMARY SOURCES 38
2.1.3.1 Insights from primary experts 39
2.2 MARKET SIZE ESTIMATION 41
2.3 DATA TRIANGULATION APPROACH 47
2.4 MARKET SHARE ANALYSIS 47
2.5 STUDY ASSUMPTIONS 48
2.6 RESEARCH LIMITATIONS 48
2.6.1 METHODOLOGY-RELATED LIMITATIONS 48
2.7 RISK ASSESSMENT 49
3 EXECUTIVE SUMMARY 50
4 PREMIUM INSIGHTS 56
4.1 INTERVENTIONAL CARDIOLOGY DEVICES MARKET OVERVIEW 56
4.2 ASIA PACIFIC: INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER 57
4.3 INTERVENTIONAL CARDIOLOGY DEVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 58
4.4 REGIONAL MIX: INTERVENTIONAL CARDIOLOGY DEVICES MARKET (2022–2029) 59
 
5 MARKET OVERVIEW 60
5.1 INTRODUCTION 60
5.2 MARKET DYNAMICS 60
5.2.1 DRIVERS 61
5.2.1.1 Growing prevalence of cardiovascular diseases 61
5.2.1.2 Rising technological investments in interventional cardiology procedures 62
5.2.1.3 Increasing prevalence of diabetes 63
5.2.1.4 Favorable regulatory support 63
5.2.2 RESTRAINTS 64
5.2.2.1 Availability of alternative treatments 64
5.2.2.2 Product recalls 65
5.2.3 OPPORTUNITIES 65
5.2.3.1 High growth potential in emerging markets 65
5.2.3.2 Increasing demand for coronary stents 66
5.2.4 CHALLENGES 67
5.2.4.1 Stringent regulatory requirements for product approvals 67
5.3 INDUSTRY TRENDS 68
5.3.1 DRUG-ELUTING TECHNOLOGIES 68
5.3.2 INCREASING EMPHASIS ON MINIMALLY INVASIVE PROCEDURES 68
5.4 SUPPLY CHAIN ANALYSIS 69
5.5 VALUE CHAIN ANALYSIS 71
5.6 TECHNOLOGY ANALYSIS 72
5.6.1 KEY TECHNOLOGIES 72
5.6.1.1 TAVR technology 72
5.6.2 ADJACENT TECHNOLOGIES 73
5.6.3 COMPLEMENTARY TECHNOLOGIES 74
5.6.3.1 Integration of real-time monitoring into wearable technologies 74
5.6.3.2 Precise cardiovascular interventions through artificial intelligence 75
5.7 PORTER’S FIVE FORCES ANALYSIS 76
5.7.1 THREAT OF NEW ENTRANTS 77
5.7.2 THREAT OF SUBSTITUTES 77
5.7.3 BARGAINING POWER OF SUPPLIERS 77
5.7.4 BARGAINING POWER OF BUYERS 77
5.7.5 INTENSITY OF COMPETITIVE RIVALRY 78
5.8 REGULATORY LANDSCAPE 78
5.8.1 REGULATORY ANALYSIS 78
5.8.1.1 North America 78
5.8.1.1.1 US 78
5.8.1.2 Europe 79
5.8.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 80
5.9 PRICING ANALYSIS 83
5.9.1 INDICATIVE AVERAGE SELLING PRICE OF KEY PLAYERS, BY PRODUCT TYPE, 2023 83
5.9.2 INDICATIVE AVERAGE SELLING PRICE OF INTERVENTIONAL CARDIOLOGY DEVICES, BY PRODUCT TYPE, 2023 84
5.9.3 INDICATIVE AVERAGE SELLING PRICE, BY REGION 84
5.10 ECOSYSTEM ANALYSIS 85
5.11 PATENT ANALYSIS 87
5.11.1 PATENT PUBLICATION TRENDS FOR INTERVENTIONAL CARDIOLOGY DEVICES 87
5.11.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 87
5.12 TRADE ANALYSIS 90
5.12.1 TRADE ANALYSIS FOR INTERVENTIONAL CARDIOLOGY DEVICES AND CONSUMABLES 90
5.12.2 HS CODES 90
5.13 KEY CONFERENCES & EVENTS, 2024−2025 92
5.14 KEY STAKEHOLDERS & BUYING CRITERIA 93
5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS 93
5.14.2 BUYING CRITERIA 94
5.15 UNMET NEEDS/END-USER EXPECTATIONS 95
5.16 IMPACT OF AI/GEN AI ON INTERVENTIONAL CARDIOLOGY DEVICES MARKET 96
5.17 CASE STUDY ANALYSIS 96
5.17.1 CASE STUDY 1: BOSTON SCIENTIFIC CORPORATION USES GUIDEZILLA II EXTENSION CATHETER FOR PC INTERVENTIONS 96
5.17.2 CASE STUDY 2: MEDTRONIC PROVIDES CARDIOLOGY DEVICES FOR VENOUS INTERVENTIONS 97
5.17.3 CASE STUDY 3: ABOTT OFFERS DRUG-ELUTING STENTS FOR PATIENTS WITH HIGHER RISK OF STROKE 97
5.18 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 98
5.19 ADJACENT MARKETS FOR INTERVENTIONAL CARDIOLOGY DEVICES 99
5.20 INVESTMENT & FUNDING SCENARIO 99
6 ANGIOPLASTY STENTS MARKET, BY TYPE 100
6.1 INTRODUCTION 101
6.1.1 DRUG-ELUTING STENTS 103
6.1.1.1 Drug-eluting stents to hold largest share of angioplasty stents market 103
6.1.2 BARE-METAL STENTS 105
6.1.2.1 Increasing use of drug-eluting stents to limit growth of bare-metal stents market 105
6.1.3 BIOABSORBABLE STENTS 107
6.1.3.1 Ability of bioabsorbable stents to ensure complete healing of arteries to propel demand 107
 
7 STRUCTURAL HEART DEVICES MARKET, BY TYPE 109
7.1 INTRODUCTION 110
7.1.1 AORTIC VALVE THERAPY DEVICES 111
7.1.1.1 Increasing prevalence of aortic valve stenosis to support market growth 111
7.1.2 OTHER THERAPY DEVICES 113
8 CATHETERS MARKET, BY TYPE 116
8.1 INTRODUCTION 117
8.1.1 ANGIOGRAPHY CATHETERS 119
8.1.1.1 Rising cases of artery disease and heart attacks to propel market 119
8.1.2 GUIDING CATHETERS 121
8.1.2.1 Increasing number of angiography procedures to drive the market 121
8.1.3 IVUS/OCT CATHETERS 123
8.1.3.1 Ability to obtain 3D images for aneurysm assessment to support market growth 123
9 ANGIOPLASTY BALLOONS MARKET, BY TYPE 126
9.1 INTRODUCTION 127
9.1.1 OLD/NORMAL BALLOONS 128
9.1.1.1 Low treatment costs associated with old/normal balloons to drive growth 128
9.1.2 DRUG-ELUTING BALLOONS 130
9.1.2.1 Rising number of regulatory approvals for drug-eluting balloons to support market growth during forecast period 130
9.1.3 CUTTING/SCORING BALLOONS 132
9.1.3.1 Limited use of cutting balloon-aided procedures to restrain market growth 132
10 PLAQUE MODIFICATION DEVICES MARKET, BY TYPE 134
10.1 INTRODUCTION 135
10.1.1 THROMBECTOMY DEVICES 137
10.1.1.1 Ability to remove blood clots in STEMI and NSTEMI patients to propel market 137
10.1.2 ATHERECTOMY DEVICES 138
10.1.2.1 Increasing use of lipid-modifying drugs for atherosclerosis to support market growth 138
11 HEMODYNAMIC FLOW ALTERATION DEVICES MARKET, BY TYPE 140
11.1 INTRODUCTION 141
11.1.1 EMBOLIC PROTECTION DEVICES 142
11.1.1.1 Adoption of filter & occlusion-based devices to propel market 142
11.1.2 CHRONIC TOTAL OCCLUSION DEVICES 144
11.1.2.1 Uptake in treatment of total occlusions to drive market 144
12 OTHER INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY TYPE 145
12.1 INTRODUCTION 146
12.1.1 GUIDEWIRES 147
12.1.1.1 Growing demand for stent placements and coronary intervention procedures to propel market 147
12.1.2 VASCULAR CLOSURE DEVICES 149
12.1.2.1 Ability to provide increased efficacy in patient outcomes to fuel uptake 149
12.1.3 INTRODUCER SHEATHS 150
12.1.3.1 Ability to provide secure access to blood vessels to support market growth 150
12.1.4 BALLOON INFLATION DEVICES 151
12.1.4.1 Increasing incidence of peripheral artery disease to drive market 151
12.1.5 HEMOSTASIS HEART VALVES 153
12.1.5.1 Growing focus on precision medicine 153
13 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY END USER 154
13.1 INTRODUCTION 155
13.2 HOSPITALS 155
13.2.1 AVAILABILITY OF ADVANCED INFRASTRUCTURE AND SPECIALIZED EQUIPMENT TO DRIVE MARKET 155
13.3 AMBULATORY SURGERY CENTERS 157
13.3.1 LOW CASES OF HAIS AND SHORTER RECOVERY TIMES TO PROPEL MARKET 157
13.4 OTHER END USERS 159
14 INTERVENTIONAL CARDIOLOGY DEVICES MARKET, BY REGION 160
14.1 INTRODUCTION 161
14.2 NORTH AMERICA 162
14.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 162
14.2.2 US 167
14.2.2.1 Availability of reimbursements for cardiology procedures to drive market 167
14.2.3 CANADA 171
14.2.3.1 Rising prevalence of chronic diseases to drive market 171
14.3 EUROPE 175
14.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 176
14.3.2 GERMANY 180
14.3.2.1 Growing hub for advanced technology product distributors to drive market 180
14.3.3 FRANCE 184
14.3.3.1 Favorable government initiatives in France to support market growth 184
14.3.4 UK 188
14.3.4.1 Growing focus on personalized medicine to fuel uptake 188
 
14.3.5 ITALY 192
14.3.5.1 Increasing cases of obesity and CVD to support market growth 192
14.3.6 SPAIN 196
14.3.6.1 Increasing prevalence of age-related CVD conditions to drive market 196
14.3.7 REST OF EUROPE 200
14.4 ASIA PACIFIC 204
14.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 204
14.4.2 CHINA 209
14.4.2.1 High tobacco consumption and increasing cases of CVD to fuel uptake 209
14.4.3 JAPAN 213
14.4.3.1 Increasing demand for stents and catheters to support market growth 213
14.4.4 INDIA 217
14.4.4.1 Improvements in angioplasty devices to fuel uptake 217
14.4.5 AUSTRALIA 221
14.4.5.1 Increasing cases of lifestyle disorders to support market growth 221
14.4.6 SOUTH KOREA 225
14.4.6.1 Growth in pharmaceutical sectors to propel market 225
14.4.7 REST OF ASIA PACIFIC 229
14.5 LATIN AMERICA 233
14.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 233
14.5.2 BRAZIL 237
14.5.2.1 Rising demand for quality treatment and focus on growing healthcare infrastructure to drive market 237
14.5.3 MEXICO 241
14.5.3.1 Increasing cases of diabetes to fuel market 241
14.5.4 REST OF LATIN AMERICA 245
14.6 MIDDLE EAST & AFRICA 249
14.6.1 MIDDLE EAST & AFRICA: MACROECONOMIC OUTLOOK 249
14.6.2 GCC COUNTRIES 253
14.6.3 REST OF MIDDLE EAST & AFRICA 257
15 COMPETITIVE LANDSCAPE 262
15.1 OVERVIEW 262
15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 262
15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN INTERVENTIONAL CARDIOLOGY DEVICES MARKET 263
15.3 REVENUE ANALYSIS 264
15.4 MARKET SHARE ANALYSIS 265
15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 268
15.5.1 STARS 268
15.5.2 EMERGING LEADERS 268
15.5.3 PERVASIVE PLAYERS 268
15.5.4 PARTICIPANTS 268
15.6 COMPANY FOOTPRINT 270
15.6.1 COMPANY FOOTPRINT: KEY PLAYERS, 2023 270
15.6.1.1 Company footprint 270
15.6.1.2 Region footprint 271
15.6.1.3 Product footprint 272
15.6.1.4 Angioplasty stents footprint 274
15.6.1.5 Structural heart devices footprint 275
15.6.1.6 Catheters footprint 276
15.6.1.7 Angioplasty balloons footprint 277
15.6.1.8 Plaque modification devices footprint 278
15.6.1.9 Hemodynamic flow alteration devices footprint 279
15.6.1.10 Other interventional cardiology devices footprint 280
15.6.1.11 End-user footprint 281
15.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 282
15.7.1 PROGRESSIVE COMPANIES 282
15.7.2 RESPONSIVE COMPANIES 282
15.7.3 DYNAMIC COMPANIES 282
15.7.4 STARTING BLOCKS 282
15.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 284
15.8 COMPANY VALUATION & FINANCIAL METRICS 286
15.8.1 FINANCIAL METRICS 286
15.8.2 COMPANY VALUATION 286
15.9 BRAND/PRODUCT COMPARATIVE ANALYSIS 287
15.10 R&D ASSESSMENT OF KEY PLAYERS 288
15.11 COMPETITIVE SCENARIO 288
15.11.1 PRODUCT LAUNCHES & APPROVALS 288
15.11.2 DEALS 289
15.11.3 EXPANSIONS 290
16 COMPANY PROFILES 291
16.1 KEY PLAYERS 291
16.1.1 BOSTON SCIENTIFIC CORPORATION 291
16.1.1.1 Business overview 291
16.1.1.2 Products offered 292
16.1.1.3 Recent developments 295
16.1.1.3.1 Product launches & approvals 295
16.1.1.3.2 Deals 296
16.1.1.4 MnM view 297
16.1.1.4.1 Key strengths 297
16.1.1.4.2 Strategic choices 297
16.1.1.4.3 Weaknesses & competitive threats 297
16.1.2 MEDTRONIC 298
16.1.2.1 Business overview 298
16.1.2.2 Products offered 299
16.1.2.3 Recent developments 302
16.1.2.3.1 Product launches & approvals 302
16.1.2.3.2 Deals 303
16.1.2.4 MnM view 303
16.1.2.4.1 Key strengths 303
16.1.2.4.2 Strategic choices 303
16.1.2.4.3 Weaknesses & competitive threats 303
16.1.3 ABBOTT 304
16.1.3.1 Business overview 304
16.1.3.2 Products offered 305
16.1.3.3 Recent developments 307
16.1.3.3.1 Product launches & approvals 307
16.1.3.3.2 Deals 308
16.1.3.4 MnM view 308
16.1.3.4.1 Key strengths 308
16.1.3.4.2 Strategic choices 308
16.1.3.4.3 Weaknesses & competitive threats 308
16.1.4 KONINKLIJKE PHILIPS N.V. 309
16.1.4.1 Business overview 309
16.1.4.2 Products offered 310
16.1.4.3 Recent developments 311
16.1.4.3.1 Deals 311
16.1.5 TERUMO CORPORATION 312
16.1.5.1 Business overview 312
16.1.5.2 Products offered 313
16.1.5.3 Recent developments 315
16.1.5.3.1 Product launches 315
16.1.5.3.2 Expansions 315
16.1.5.4 MnM view 315
16.1.5.4.1 Key strengths 315
16.1.5.4.2 Strategic choices 315
16.1.5.4.3 Weaknesses & competitive threats 316
16.1.6 EDWARDS LIFESCIENCES CORPORATION 317
16.1.6.1 Business overview 317
16.1.6.2 Products offered 318
16.1.6.3 Recent developments 319
16.1.6.3.1 Product launches & approvals 319
16.1.6.3.2 Deals 320
 
16.1.7 B. BRAUN SE 321
16.1.7.1 Business overview 321
16.1.7.2 Products offered 322
16.1.7.3 Recent developments 324
16.1.7.3.1 Product launches & approvals 324
16.1.7.3.2 Deals 324
16.1.8 INTEGER HOLDINGS CORPORATION 325
16.1.8.1 Business overview 325
16.1.8.2 Products offered 326
16.1.8.3 Recent developments 327
16.1.8.3.1 Deals 327
16.1.8.3.2 Expansions 328
16.1.9 TELEFLEX INCORPORATED 329
16.1.9.1 Business overview 329
16.1.9.2 Products offered 330
16.1.9.3 Recent developments 331
16.1.9.3.1 Product approvals 331
16.1.10 PENUMBRA, INC. 333
16.1.10.1 Business overview 333
16.1.10.2 Products offered 334
16.1.10.3 Recent developments 335
16.1.10.3.1 Product launches & approvals 335
16.1.11 COOK 336
16.1.11.1 Business overview 336
16.1.11.2 Products offered 336
16.1.11.3 Recent developments 338
16.1.11.3.1 Deals 338
16.1.12 CORDIS 339
16.1.12.1 Business overview 339
16.1.12.2 Products offered 339
16.1.12.3 Recent developments 340
16.1.12.3.1 Product launches & approvals 340
16.1.12.3.2 Deals 340
16.1.13 IVASCULAR S.L.U. 341
16.1.13.1 Business overview 341
16.1.13.2 Products offered 341
16.1.14 BIOSENSORS INTERNATIONAL GROUP, LTD. 342
16.1.14.1 Business overview 342
16.1.14.2 Products offered 342
16.1.14.3 Recent developments 343
16.1.14.3.1 Product launches 343
 
16.1.15 BIOTRONIK SE & CO. KG 344
16.1.15.1 Business overview 344
16.1.15.2 Products offered 344
16.1.15.3 Recent developments 345
16.1.15.3.1 Product launches 345
16.2 OTHER PLAYERS 346
16.2.1 AMG INTERNATIONAL (SUBSIDIARY OF Q3 MEDICAL) 346
16.2.2 ENDOCOR GMBH & CO. KG 347
16.2.3 INSITU TECHNOLOGIES, INC. 348
16.2.4 MERIL LIFE SCIENCES PVT. LTD 349
16.2.5 ALVIMEDICA 350
16.2.6 CARDIONOVUM GMBH 351
16.2.7 MEDINOL 352
16.2.8 WELLINQ 353
16.2.9 BALTON SP. 354
16.2.10 TRANSLUMINA 355
17 APPENDIX 356
17.1 DISCUSSION GUIDE 356
17.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 362
17.3 CUSTOMIZATION OPTIONS 364
17.4 RELATED REPORTS 364
17.5 AUTHOR DETAILS 365